Maxigen Biotech Inc. (TPE:1783)

Maxigen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	745.77	576.19	639.05	431.08	790.95	513.31
Short-Term Investments	251.5	300	-	-	8.82	13.84
Cash & Short-Term Investments	997.27	876.19	639.05	431.08	799.76	527.15
Cash Growth	35.17%	37.11%	48.24%	-46.10%	51.72%	151.31%
Accounts Receivable	129.84	132.19	103.91	88.31	98.86	109.95
Other Receivables	0	-	-	8.75	1.42	4.76
Receivables	129.84	132.19	103.91	97.06	100.27	114.71
Inventory	90.92	99.19	75.76	85.32	75.41	80.63
Prepaid Expenses	16.94	11.97	9.82	4.52	15.41	47.78
Other Current Assets	1.19	1.93	1.79	1.58	2.39	13.29
Total Current Assets	1,236	1,121	830.33	619.56	993.25	783.55
Property, Plant & Equipment	450.46	442.83	430.36	424.18	434.62	465.45
Long-Term Investments	291.06	279.68	311.31	432.8	-	-
Other Intangible Assets	0.56	0.73	0.13	0.49	1.16	1.83
Long-Term Deferred Tax Assets	2.14	1.13	2.55	5.83	3.19	0.38
Other Long-Term Assets	52.56	47.31	7.81	10.13	15.5	13.97
Total Assets	2,033	1,893	1,582	1,493	1,448	1,265

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	115.54	88.22	49.98	17.17	35.94	40.15
Accrued Expenses	-	83.11	72.07	64.63	55.35	40.35
Short-Term Debt	100	100	-	-	-	-
Current Portion of Leases	-	-	-	-	-	2.36
Current Income Taxes Payable	18.35	29.61	25.52	24.47	27.17	9.28
Current Unearned Revenue	12.14	15.1	22.93	1.34	4.25	11.13
Other Current Liabilities	283.78	33.07	35.37	23.78	28.79	12.8
Total Current Liabilities	529.8	349.11	205.87	131.37	151.5	116.07
Long-Term Leases	-	-	-	-	-	7.28
Long-Term Deferred Tax Liabilities	1.1	1.18	0.93	0.49	0.55	-
Other Long-Term Liabilities	3.12	5.26	0.56	0.02	0.02	0.12
Total Liabilities	534.02	355.54	207.36	131.88	152.07	123.47

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	896.98	896.8	891.63	889.34	846.99	769.99
Additional Paid-In Capital	331.64	331.29	326.93	296.1	281.9	264.39
Retained Earnings	487.03	534.5	344.12	244.46	169.8	110.3
Comprehensive Income & Other	-216.74	-225	-187.56	-68.79	-3.04	-2.96
Total Common Equity	1,499	1,538	1,375	1,361	1,296	1,142
Shareholders' Equity	1,499	1,538	1,375	1,361	1,296	1,142
Total Liabilities & Equity	2,033	1,893	1,582	1,493	1,448	1,265

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	100	100	-	-	-	9.64
Net Cash (Debt)	897.27	776.19	639.05	431.08	799.76	517.51
Net Cash Growth	21.62%	21.46%	48.24%	-46.10%	54.54%	161.86%
Net Cash Per Share	9.90	8.59	7.12	4.82	8.95	6.12
Filing Date Shares Outstanding	89.92	89.68	89.16	88.93	88.93	88.93
Total Common Shares Outstanding	89.92	89.68	89.16	88.93	88.93	88.93
Working Capital	706.35	772.36	624.47	488.19	841.75	667.49
Book Value Per Share	16.67	17.15	15.42	15.30	14.57	12.84
Tangible Book Value	1,498	1,537	1,375	1,361	1,294	1,140
Tangible Book Value Per Share	16.66	17.14	15.42	15.30	14.56	12.82
Land	-	133.23	133.23	133.23	133.23	133.23
Buildings	-	-	310.48	307.74	303.11	302.48
Machinery	-	542.5	181.24	160.52	149.88	162
Construction In Progress	-	13.01	20.08	17.67	21.6	18.79
Leasehold Improvements	-	13.43	13.43	18.91	18.91	23.7

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error